Surgical outcomes of prolactinomas in recent era: Results of a heterogenous group

Diane Donegan, John L.D. Atkinson, Mark Jentoft, Neena Natt, Tod B. Nippoldt, Bradley J Erickson, Fredric Meyer, Dana Erickson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: Prolactinomas are primarily treated with medical therapy. Given the efficacy of dopamine agonists (DAs), surgery has remained a second-line treatment option. Despite medical therapy, some tumors display resistance and/or patients maybe intolerant of DA and require alternative treatment options. We examined the indications, efficacy, and safety of pituitary surgery for the treatment of prolactinomas. Methods: We performed a retrospective analysis of all patients who had surgery for a prolactinoma at our institution from January 1993 to October 2014. Results: Seventy-eight patients (46 females, mean age 32 years) with a median follow-up of 12 months were analyzed. Macroprolactinomas accounted for 65% (51/78) of tumors. The most common indication for surgery in microprolactinomas was medication intolerance (37%, 10/27) and medication failure (33%, 17/51) in macroprolactinomas. DA therapy had been tried in 76% (59/78) patients prior to surgery. Following surgery, long-term remission was seen in 72% (18/25) of micro-adenomas and 20% (10/49) of macro-adenomas (32% [10/32] in those without cavernous sinus invasion). Despite persistent disease in those with macro-adenomas (34% [13/38]) were able to remain off medication. Early surgical failure was more common in males (P =.004) and those with large (P≤.001) or atypical (P =.003) adenomas. Conclusion: Surgery can result in prolonged remission in 72% of microprolactinomas. Despite lower remission rates among macroprolactinomas, a third of patients with persistent disease did not require medical therapy. Therefore, surgery remains an alternative effective treatment option, particularly for those who are intolerant or resistant to medical therapy.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalEndocrine Practice
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Prolactinoma
Adenoma
Dopamine Agonists
Therapeutics
Cavernous Sinus
Neoplasms
Safety

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Donegan, D., Atkinson, J. L. D., Jentoft, M., Natt, N., Nippoldt, T. B., Erickson, B. J., ... Erickson, D. (2017). Surgical outcomes of prolactinomas in recent era: Results of a heterogenous group. Endocrine Practice, 23(1), 37-45. https://doi.org/10.4158/EP161446.OR

Surgical outcomes of prolactinomas in recent era : Results of a heterogenous group. / Donegan, Diane; Atkinson, John L.D.; Jentoft, Mark; Natt, Neena; Nippoldt, Tod B.; Erickson, Bradley J; Meyer, Fredric; Erickson, Dana.

In: Endocrine Practice, Vol. 23, No. 1, 01.01.2017, p. 37-45.

Research output: Contribution to journalArticle

Donegan, D, Atkinson, JLD, Jentoft, M, Natt, N, Nippoldt, TB, Erickson, BJ, Meyer, F & Erickson, D 2017, 'Surgical outcomes of prolactinomas in recent era: Results of a heterogenous group', Endocrine Practice, vol. 23, no. 1, pp. 37-45. https://doi.org/10.4158/EP161446.OR
Donegan, Diane ; Atkinson, John L.D. ; Jentoft, Mark ; Natt, Neena ; Nippoldt, Tod B. ; Erickson, Bradley J ; Meyer, Fredric ; Erickson, Dana. / Surgical outcomes of prolactinomas in recent era : Results of a heterogenous group. In: Endocrine Practice. 2017 ; Vol. 23, No. 1. pp. 37-45.
@article{e36692a750b34fdbab474b79252d4585,
title = "Surgical outcomes of prolactinomas in recent era: Results of a heterogenous group",
abstract = "Objective: Prolactinomas are primarily treated with medical therapy. Given the efficacy of dopamine agonists (DAs), surgery has remained a second-line treatment option. Despite medical therapy, some tumors display resistance and/or patients maybe intolerant of DA and require alternative treatment options. We examined the indications, efficacy, and safety of pituitary surgery for the treatment of prolactinomas. Methods: We performed a retrospective analysis of all patients who had surgery for a prolactinoma at our institution from January 1993 to October 2014. Results: Seventy-eight patients (46 females, mean age 32 years) with a median follow-up of 12 months were analyzed. Macroprolactinomas accounted for 65{\%} (51/78) of tumors. The most common indication for surgery in microprolactinomas was medication intolerance (37{\%}, 10/27) and medication failure (33{\%}, 17/51) in macroprolactinomas. DA therapy had been tried in 76{\%} (59/78) patients prior to surgery. Following surgery, long-term remission was seen in 72{\%} (18/25) of micro-adenomas and 20{\%} (10/49) of macro-adenomas (32{\%} [10/32] in those without cavernous sinus invasion). Despite persistent disease in those with macro-adenomas (34{\%} [13/38]) were able to remain off medication. Early surgical failure was more common in males (P =.004) and those with large (P≤.001) or atypical (P =.003) adenomas. Conclusion: Surgery can result in prolonged remission in 72{\%} of microprolactinomas. Despite lower remission rates among macroprolactinomas, a third of patients with persistent disease did not require medical therapy. Therefore, surgery remains an alternative effective treatment option, particularly for those who are intolerant or resistant to medical therapy.",
author = "Diane Donegan and Atkinson, {John L.D.} and Mark Jentoft and Neena Natt and Nippoldt, {Tod B.} and Erickson, {Bradley J} and Fredric Meyer and Dana Erickson",
year = "2017",
month = "1",
day = "1",
doi = "10.4158/EP161446.OR",
language = "English (US)",
volume = "23",
pages = "37--45",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "1",

}

TY - JOUR

T1 - Surgical outcomes of prolactinomas in recent era

T2 - Results of a heterogenous group

AU - Donegan, Diane

AU - Atkinson, John L.D.

AU - Jentoft, Mark

AU - Natt, Neena

AU - Nippoldt, Tod B.

AU - Erickson, Bradley J

AU - Meyer, Fredric

AU - Erickson, Dana

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: Prolactinomas are primarily treated with medical therapy. Given the efficacy of dopamine agonists (DAs), surgery has remained a second-line treatment option. Despite medical therapy, some tumors display resistance and/or patients maybe intolerant of DA and require alternative treatment options. We examined the indications, efficacy, and safety of pituitary surgery for the treatment of prolactinomas. Methods: We performed a retrospective analysis of all patients who had surgery for a prolactinoma at our institution from January 1993 to October 2014. Results: Seventy-eight patients (46 females, mean age 32 years) with a median follow-up of 12 months were analyzed. Macroprolactinomas accounted for 65% (51/78) of tumors. The most common indication for surgery in microprolactinomas was medication intolerance (37%, 10/27) and medication failure (33%, 17/51) in macroprolactinomas. DA therapy had been tried in 76% (59/78) patients prior to surgery. Following surgery, long-term remission was seen in 72% (18/25) of micro-adenomas and 20% (10/49) of macro-adenomas (32% [10/32] in those without cavernous sinus invasion). Despite persistent disease in those with macro-adenomas (34% [13/38]) were able to remain off medication. Early surgical failure was more common in males (P =.004) and those with large (P≤.001) or atypical (P =.003) adenomas. Conclusion: Surgery can result in prolonged remission in 72% of microprolactinomas. Despite lower remission rates among macroprolactinomas, a third of patients with persistent disease did not require medical therapy. Therefore, surgery remains an alternative effective treatment option, particularly for those who are intolerant or resistant to medical therapy.

AB - Objective: Prolactinomas are primarily treated with medical therapy. Given the efficacy of dopamine agonists (DAs), surgery has remained a second-line treatment option. Despite medical therapy, some tumors display resistance and/or patients maybe intolerant of DA and require alternative treatment options. We examined the indications, efficacy, and safety of pituitary surgery for the treatment of prolactinomas. Methods: We performed a retrospective analysis of all patients who had surgery for a prolactinoma at our institution from January 1993 to October 2014. Results: Seventy-eight patients (46 females, mean age 32 years) with a median follow-up of 12 months were analyzed. Macroprolactinomas accounted for 65% (51/78) of tumors. The most common indication for surgery in microprolactinomas was medication intolerance (37%, 10/27) and medication failure (33%, 17/51) in macroprolactinomas. DA therapy had been tried in 76% (59/78) patients prior to surgery. Following surgery, long-term remission was seen in 72% (18/25) of micro-adenomas and 20% (10/49) of macro-adenomas (32% [10/32] in those without cavernous sinus invasion). Despite persistent disease in those with macro-adenomas (34% [13/38]) were able to remain off medication. Early surgical failure was more common in males (P =.004) and those with large (P≤.001) or atypical (P =.003) adenomas. Conclusion: Surgery can result in prolonged remission in 72% of microprolactinomas. Despite lower remission rates among macroprolactinomas, a third of patients with persistent disease did not require medical therapy. Therefore, surgery remains an alternative effective treatment option, particularly for those who are intolerant or resistant to medical therapy.

UR - http://www.scopus.com/inward/record.url?scp=85022336254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022336254&partnerID=8YFLogxK

U2 - 10.4158/EP161446.OR

DO - 10.4158/EP161446.OR

M3 - Article

C2 - 27682355

AN - SCOPUS:85022336254

VL - 23

SP - 37

EP - 45

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 1

ER -